Related Experiment Video
Updated: Jul 12, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Abstract:
Tarlatamab, an investigational bispecific T-cell engager molecule that targets the cell surface protein delta-like ligand 3, has shown promising activity in patients with small cell lung cancer whose disease had progressed after receiving another therapy. Questions remain over whether clinicians and patients would use the drug given its challenging administration.
Insights
Tarlatamab shows promise in treating advanced small cell lung cancer. However, its complex administration may affect its clinical use by doctors and patients.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Small cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options for relapsed disease.
- Delta-like ligand 3 (DLL3) is a protein expressed in SCLC, making it a target for novel therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of tarlatamab, a bispecific T-cell engager targeting DLL3, in patients with relapsed SCLC.
- To assess the potential clinical utility of tarlatamab considering its administration requirements.
Main Methods:
- Tarlatamab, a bispecific T-cell engager, was administered to patients with SCLC.
- Patient outcomes, including treatment activity and adverse events, were monitored.
Main Results:
- Tarlatamab demonstrated promising anti-tumor activity in patients with SCLC that progressed after prior therapy.
- The study identified potential challenges related to the drug's administration.
Conclusions:
- Tarlatamab represents a potential new therapeutic option for patients with relapsed SCLC.
- Further investigation is needed to address administration challenges and optimize clinical adoption.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
